MarketBeat·1d ago
Oura's $15.6 Billion IPO Is Betting Investors See More Than a Smart RingOura Inc. NASDAQ: OURA launched its roadshow on Sept. 21, 2026, targeting a Nasdaq debut under the ticker OURA during the week of Sept.
Eli Lilly's explosive growth is fueled by its GLP-1 franchise, with revenue accelerating to $23.0B in 2026Q2 (up 47.7% YoY) and gross margins expanding to 85.8%. However, this growth is capital-intensive, as evidenced by debt rising to $54.9B (D/E of 1.62) and...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 47.7% YoY in 2026Q2, with gross margin expanding to 85.8% from 80.8% in 2024Q2, though operating margin dipped to 39.1% from 45.8% a year ago, suggesting temporary cost pressures.
Eli Lilly reported a 56% year-over-year revenue increase to $19.8 billion in Q1 2026, with EPS up 170% to $8.26.
Mounjaro and Zepbound are projected to generate over $50 billion in revenue in 2026, with Foundayo expected to earn $1.6 billion.
Eli Lilly's $50 billion investment in manufacturing and a deep pipeline, including retatrutide, positions it for sustained leadership.
The stock's P/E ratio of 40.5x is significantly higher than the industry average of 16.1x, leaving little room for error.
The GLP-1 market faces threats from competitors like Novo Nordisk, with oral Wegovy potentially offering superior weight loss benefits.
Risks for drugs like Kisunla include bottlenecks in patient diagnosis and potential cannibalization of existing products.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $8.38+30.9% vs $6.40 | $23.0B+10.3% vs $20.8B |
Q2 2026 Apr 30, 2026 | $8.55+22.7% vs $6.97 | $19.8B+11.1% vs $17.8B |
Q1 2026 Feb 4, 2026 | $7.54+9.1% vs $6.91 | $19.3B+7.5% vs $17.9B |
Q4 2025 Oct 30, 2025 | $7.02+23.4% vs $5.69 | $17.6B+9.6% vs $16.1B |
Oura Inc. NASDAQ: OURA launched its roadshow on Sept. 21, 2026, targeting a Nasdaq debut under the ticker OURA during the week of Sept.
The U.S. Food and Drug Administration (FDA) on Friday granted full approval to Eli Lilly and Co.'s (NYSE:LLY) Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for pretreated breast cancer patients.
Eli Lilly's yield of 0.6% looks minimal, but that's only because of how incredibly well the stock has performed. Pfizer has one of the highest yields on the S&P 500, but many investors are fearful that it's too risky.
NVO's CagriSema delivers greater weight loss than Eli Lilly's tirzepatide in T2D and 21% weight loss in obesity, strengthening its late-stage pipeline.
Benchmark LLY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Eli Lilly and Company (LLY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1170.48 | $1.1T | 51.00 | 44.7% | 31.66% | 101.15% | 0.51% | |
| $39.40 | $174.96B | 11.15 | 6.43% | 35.35% | 59.09% | — | |
| $27.93 | $159.19B | 20.54 | -1.65% | 6.81% | 4.87% | — | |
| $150.92 | $372.73B | 20.73 | 1.18% | 4.78% | 6.59% | — | |
| $168.37 | $130.49B | 12.87 | 8.63% | 17.02% | 21.72% | — | |
| $62.25 | $127.12B | 18.04 | -0.22% | 18.87% | 46.69% | — |
Eli Lilly and Company (LLY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Eli Lilly and Company (LLY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
May 20, 2026·SEC
May 7, 2026·SEC
Feb 12, 2026·SEC
Get notified when LLY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Eli Lilly and Company (LLY) stock FAQ — growth, dividends, profitability & financials explained
Eli Lilly and Company (LLY) reported $79.67B in revenue for fiscal year 2025. This represents a 1038% increase from $7.00B in 1996.
Eli Lilly and Company (LLY) grew revenue by 44.7% over the past year. This is strong growth.
Yes, Eli Lilly and Company (LLY) is profitable, generating $26.71B in net income for fiscal year 2025 (31.7% net margin).
Yes, Eli Lilly and Company (LLY) pays a dividend with a yield of 0.51%. This makes it attractive for income-focused investors.
Eli Lilly and Company (LLY) has a return on equity (ROE) of 101.2%. This is excellent, indicating efficient use of shareholder capital.
Eli Lilly and Company (LLY) generated $20.05B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
